Thilo Schroeder - Mar 7, 2022 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role: Director
Signature: /s/ Darren DeStefano, Attorney-in-Fact
Stock symbol: RVMD
Transactions as of: Mar 7, 2022
Transactions value $: $4,660,856
Form type: 4
Date filed: 3/9/2022, 07:45 PM
Previous filing: Oct 8, 2021
Next filing: Mar 14, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RVMD	Common Stock	Purchase	$1.76M	+95.9K	+40.27%	$18.35	334K	Mar 7, 2022	By Nextech Crossover I SCSP	F1, F2
transaction	RVMD	Common Stock	Purchase	$134K	+7.08K	+2.12%	$18.91	341K	Mar 7, 2022	By Nextech Crossover I SCSP	F2, F3
transaction	RVMD	Common Stock	Purchase	$782K	+42.9K	+12.57%	$18.23	384K	Mar 8, 2022	By Nextech Crossover I SCSP	F2, F4
transaction	RVMD	Common Stock	Purchase	$813K	+42K	+10.94%	$19.36	426K	Mar 8, 2022	By Nextech Crossover I SCSP	F2, F5
transaction	RVMD	Common Stock	Purchase	$377K	+18.9K	+4.44%	$19.90	445K	Mar 8, 2022	By Nextech Crossover I SCSP	F2, F6
transaction	RVMD	Common Stock	Purchase	$795K	+39.6K	+8.9%	$20.07	485K	Mar 9, 2022	Common Stock	F2, F7
holding	RVMD	Common Stock						2.67M	Mar 7, 2022	By Nextech V Oncology S.C.S., SICAV-SIF	F8
holding	RVMD	Common Stock						300K	Mar 7, 2022	By Nextech VI Oncology SCSp	F9

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.82 to $18.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2	Nextech Invest AG is the investment advisor of Nextech Crossover I SCSP ("Nextech Crossover"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech Crossover. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F3	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.82 to $19.03 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F4	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.70 to $18.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F5	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.70 to $19.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F6	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.70 to $20.13 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F7	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.69 to $20.68 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F8	Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F9	Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.